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Background:
In Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL) patients (pts), efficacy of
tyrosine kinase inhibitor (TKI)-based therapies is often compromised by selection of resistant
mutations in the BCR-ABL kinase domain (KD). Currently, the gold standard for BCR-ABL KD
mutation screening is conventional Sanger sequencing (SS). However, more sensitive
approaches are desirable to allow more timely and rational therapeutic intervention.
Aims:
A Deep sequencing (DS) strategy based on the Roche 454 next-generation sequencing
technology was set up in order to: study the dynamics of expansion of different types of BCR-ABL
KD mutations in Ph+ ALL patients developing resistance to TKI-based therapies; test the ability of
DS to highlight emerging clones harboring TKI-resistant mutations.
Methods:
29 Ph+ ALL pts who had developed resistance to TKI-based (imatinib, dasatinib, nilotinib)
therapies were selected for this retrospective analysis. All the pts were known to have developed
TKI-resistant BCR-ABL mutations on treatment, as assessed by SS. To reconstruct the dynamics
of mutation emergence, longitudinal re-analysis of samples from relapse backwards (n=97; 1-3
months sampling interval) was performed on a Roche GS Junior instrument. DS runs were
designed so as to enable high sensitivity mutation calling (minimum target sequence coverage
4,000 reads). However, to minimize the likelihood of false positive results, data were analyzed
filtering out all variants with <1% abundance.
Results:
DS could successfully detect all the mutations (n=85) previously identified by SS (>15%
abundance). In addition, DS revealed that both those samples that had been scored as
apparently wild-type by SS and those samples already known to harbor mutations as assessed
by SS might be carrying one or more ‘lower level’ mutations (<15% abundance). In the latter
cases, clonal analysis showed complex textures with the same mutation alone and also in
combination with other(s) (‘compound’ mutations) in distinct subclones. Some lower level
mutations were silent or apparently irrelevant from a clinical standpoint (passenger mutations?).
In more than half of the cases, however, known TKI-resistant variants could be recognized that
corresponded either to ‘withdrawing’ mutants not (yet) entirely de-selected by the switch in TKI or
to outgrowing mutations anticipating an imminent relapse. Lower level mutations were confirmed
with independent methods (ASO-PCR, RFLP). Notably, in 16/29 (55%) pts with molecularly
detectable disease but not yet evidence of cytogenetic or hematologic relapse, DS could identify
emerging mutations 1 to 3 months before they became detectable by SS. In the remaining 13 pts,
however, outgrowth of the TKI-resistant mutation (T315I=7, Y253H=2, E255K=2, E255V=1 and
F317L=1) was so rapid that not even a strict monthly monitoring could have allowed to pick them
up before they became dominant.
Summary / Conclusion:
Now that multiple options are available, BCR-ABL KD mutation monitoring is a precious tool to
maximize the efficacy of TKI-based regimens as induction or salvage therapy of Ph+ ALL. DS
proved as reliable as SS for the detection of mutations with >15% abundance. As a key
advantage, DS added precious quantitative and qualitative information on the full repertoire of
mutated populations, that SS underestimated in more than half of the samples analyzed. TKI-
resistant mutations leading to patient relapse were not necessarily preexisting at diagnosis or at
the time of switchover to another TKI, underlining the importance of regular monitoring of pts.
Although the majority of mutations were found to arise and take over very rapidly, a monthly
monitoring by our DS approach would have allowed to identify them earlier than SS actually did -
and well in advance of clinical relapse - in half of the pts. DS technologies would enable higher
sensitivity mutation calling: further studies are warranted to determine the optimal lower detection
limit to aim to in order to exclude both transient mutant subclones that will never take over and
sequencing errors.
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